title: [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
abstract: OBJECTIVE
  To investigate the variation in expression of ARHI, STAT3 and E2F1 and the correlation among them during carcinogenesis of ovarian serous carcinoma.
  
  
  METHODS
  Immunohistochemical staining was used to detect the expression of ARHI, STAT3 and E2F1 in samples of 25 normal ovaries, 35 ovarian serous cystadenomas, 18 borderline serous cystadenomas and 56 ovarian serous carcinomas. The variation in expression of the three genes and relationship among them were analyzed.
  
  
  RESULTS
  ARHI expression was detected in 22 of 25 (88.0%) normal ovaries and 30 of 35 (85.7%) cystadenomas, but only in 10 of 18 (55.6%) borderline serous cystadenomas and 22 of 56 (39.3%) ovarian serous carcinomas, significantly lower than that in the normal ovaries and ovarian serous cystadenomas (P < 0.05). STAT3 expression was found in 14 of 18 (77.8%) borderline serous cystadenomas and 49 of 56 (87.5%) ovarian serous carcinomas, significantly higher than that in the normal ovaries and ovarian serous cystadenomas (P < 0.05). To compare with E2F1 expression in the normal ovaries, serous cystadenomas and borderline serous cystadenomas, E2F1 expression in 46 of 56 (82.1%) ovarian serous carcinomas was significantly higher (P < 0.05). It was found that the expression of ARHI was inversely correlated with that of STAT3 and E2F1.
  
  
  CONCLUSIONS
  Our findings indicate that ARHI expression is down-regulated, but STAT3 and E2F1 expressions are up-regulated, with an inverse correlation between ARHI and STAT3 in the carcinogenesis of ovarian serous carcinoma.
authors.affiliation: Department of Gynecology and Obstetrics, The 4th Hospital of Hebei Medical University, Shijiazhuang 050011, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Yue-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Ai-Rong
authors.initials: AR
authors.lastname: Cui
authors.forename: Jun-Ling
authors.initials: JL
authors.lastname: Wang
authors.forename: Jian-Xin
authors.initials: JX
authors.lastname: Cheng
authors.forename: Shi-Jie
authors.initials: SJ
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D018293:Cystadenoma, Serous / Q000378:metabolism / Q000473:pathology; D050687:E2F1 Transcription Factor / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D020741:rho GTP-Binding Proteins / Q000378:metabolism*
chemical_list: C117386:DIRAS3 protein, human; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D050796:STAT3 Transcription Factor; D020741:rho GTP-Binding Proteins